Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK1 | P53350 | 3/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11971106 | 0.80 | CSNK1D (0.43) | PLK1POLBALDH1A1CSNK1D | |
| SCHEMBL11392032 | 0.71 | PDE10A (0.43) | PLK1 | |
| SCHEMBL25948844 | 0.68 | TNKS (0.33) | POLBALDH1A1 | |
| SCHEMBL25516956 | 0.67 | POLB (0.32) | POLB | |
| SCHEMBL25948845 | 0.67 | PDE10A (0.37) | POLB | |
| SCHEMBL25948904 | 0.67 | KDM4E (0.36) | POLBALDH1A1 | |
| SCHEMBL26459383 | 0.66 | PLK1 (0.49) | PLK1 | |
| SCHEMBL17254528 | 0.62 | EGLN2 (0.38) | POLBALDH1A1 | |
| SCHEMBL19939393 | 0.61 | RXFP1 (0.39) | — | |
| SCHEMBL17431859 | 0.61 | TNKS (0.37) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230242533-A9 | SUBSTITUTED FUSED HETEROAROMATIC BICYCLIC COMPOUNDS AS KINASE INHIBITORS AND THE USE THEREOF | Impact Therapeutics (Shanghai), Inc (CN) | 2023-08-03 | — | — | US | disclosed |
| WO-2020259601-A1 | SUBSTITUTED FUSED HETEROAROMATIC BICYCLIC COMPOUNDS AS KINASE INHIBITORS AND THE USE THEREOF | IMPACT THERAPEUTICS, INC (CN) | 2020-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230242533-A9 | SUBSTITUTED FUSED HETEROAROMATIC BICYCLIC COMPOUNDS AS KINASE INHIBITORS AND THE USE THEREOF | ATR, CHEK1, CHEK2 | PLK1 22/4885POLB 859/4885ALDH1A1 2238/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.